Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

Summary

This study evaluates the safety and efficacy of anlotinib in combination with nivilumab as second-line treatment in advanced NSCLC patients. The primary endpoint of the study is progression-free survival (PFS);the secondary endpoints are disease control rate (DCR), objective response rate (ORR), overall survival (OS) and safety.

Timeline

Start

2020-01-01

Primary completion

2021-07-01

Completion

2022-01-01

Drugs

Indications